Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

B. Garon, Edward; D. Hellmann, Matthew; A. Rizvi, Naiyer; Carcereny, Enric; B. Leighl, Natasha; Ahn, Myung-Ju; Paul Eder, Joseph; S. Balmanoukian, Ani; Aggarwal, Charu; Horn, Leora; Patnaik, Amita; Gubens, Matthew; S. Ramalingam, Suresh; Felip, Enriqueta; W. Goldman, Jonathan; Scalzo, Cathie; Jensen, Erin; A. Kush, Debra; Hui, Rina

doi:10.1200/jco.19.00934

Public

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

Shared by NobleBlocks on Oct 1, 2019 • 12:00 AM UTC

Authors:

Edward B. Garon

Matthew D. Hellmann

Naiyer A. Rizvi

Abstract

PURPOSE Pembrolizumab monotherapy has demonstrated durable antitumor activity in advanced programmed death ligand 1 (PD-L1)–expressing non‒small-cell lung cancer (NSCLC). We report 5-year outcomes from the phase Ib KEYNOTE-001 study. These data provide the longest efficacy and safety follow-up for p...

Discussions